The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
The global Prostate Cancer Diagnostics revenue was US$ 13430 million in 2022 and is forecast to a readjusted size of US$ 22860 million by 2029 with a CAGR of 7.8% during the review period (2023-2029).
In India, the Prostate Cancer Diagnostics revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period 2023-2029.
Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.
This report focuses on global and India Prostate Cancer Diagnostics market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Prostate Cancer Diagnostics will continue to grow rapidly in the future.
Global Prostate Cancer Diagnostics Scope and Market Size
Prostate Cancer Diagnostics market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Prostate Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.
For India market, this report focuses on the Prostate Cancer Diagnostics market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
By Company
OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics
Segment by Type
Tumor Biomarker Tests
Imaging
Biopsy
Other
Segment by Application
Age Below 55
Age 55-75
Age Above 75
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1: Introduces Prostate Cancer Diagnostics definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Detailed analysis of Prostate Cancer Diagnostics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5: Revenue of Prostate Cancer Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6: Americas by type, by application and by country revenue for each segment.
Chapter 7: EMEA by type, by application and by region, revenue for each segment.
Chapter 8: China by type, by application revenue for each segment.
Chapter 9: APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer Diagnostics revenue, gross margin and recent development, etc.
Chapter 11: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Prostate Cancer Diagnostics Product Introduction
1.2 Global Prostate Cancer Diagnostics Outlook 2018 VS 2022 VS 2029
1.2.1 Global Prostate Cancer Diagnostics Market Size for the Year 2018-2029
1.2.2 India Prostate Cancer Diagnostics Market Size for the Year 2018-2029
1.3 Prostate Cancer Diagnostics Market Size, India VS Global, 2018 VS 2022 VS 2029
1.3.1 The Market Share of India Prostate Cancer Diagnostics in Global, 2018 VS 2022 VS 2029
1.3.2 The Growth Rate of Prostate Cancer Diagnostics Market Size, India VS Global, 2018 VS 2022 VS 2029
1.4 Prostate Cancer Diagnostics Market Dynamics
1.4.1 Prostate Cancer Diagnostics Industry Trends
1.4.2 Prostate Cancer Diagnostics Market Drivers
1.4.3 Prostate Cancer Diagnostics Market Challenges
1.4.4 Prostate Cancer Diagnostics Market Restraints
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Prostate Cancer Diagnostics by Type
2.1 Prostate Cancer Diagnostics Market Segment by Type
2.1.1 Tumor Biomarker Tests
2.1.2 Imaging
2.1.3 Biopsy
2.1.4 Other
2.2 Global Prostate Cancer Diagnostics Market Size by Type (2018, 2022 & 2029)
2.3 Global Prostate Cancer Diagnostics Market Size by Type (2018-2029)
2.4 India Prostate Cancer Diagnostics Market Size by Type (2018, 2022 & 2029)
2.5 India Prostate Cancer Diagnostics Market Size by Type (2018-2029)
3 Prostate Cancer Diagnostics by Application
3.1 Prostate Cancer Diagnostics Market Segment by Application
3.1.1 Age Below 55
3.1.2 Age 55-75
3.1.3 Age Above 75
3.2 Global Prostate Cancer Diagnostics Market Size by Application (2018, 2022 & 2029)
3.3 Global Prostate Cancer Diagnostics Market Size by Application (2018-2029)
3.4 India Prostate Cancer Diagnostics Market Size by Application (2018, 2022 & 2029)
3.5 India Prostate Cancer Diagnostics Market Size by Application (2018-2029)
4 Global Prostate Cancer Diagnostics Competitor Landscape by Company
4.1 Global Prostate Cancer Diagnostics Market Size by Company
4.1.1 Global Key Companies of Prostate Cancer Diagnostics, Ranked by Revenue (2022)
4.1.2 Global Prostate Cancer Diagnostics Revenue by Player (2018-2023)
4.2 Global Prostate Cancer Diagnostics Concentration Ratio (CR)
4.2.1 Prostate Cancer Diagnostics Market Concentration Ratio (CR) (2018-2023)
4.2.2 Global Top 5 and Top 10 Largest Companies of Prostate Cancer Diagnostics in 2022
4.2.3 Global Prostate Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Players of Prostate Cancer Diagnostics Head office and Area Served
4.4 Global Key Players of Prostate Cancer Diagnostics, Product and Application
4.5 Global Key Players of Prostate Cancer Diagnostics, Date of Enter into This Industry
4.6 Companies Mergers & Acquisitions, Expansion Plans
4.7 India Prostate Cancer Diagnostics Market Size by Company
4.7.1 Key Players of Prostate Cancer Diagnostics in India, Ranked by Revenue (2022)
4.7.2 India Prostate Cancer Diagnostics Revenue by Players (2021, 2022 & 2023)
5 Global Prostate Cancer Diagnostics Market Size by Region
5.1 Global Prostate Cancer Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
5.2 Global Prostate Cancer Diagnostics Market Size by Region (2018-2029)
5.2.1 Global Prostate Cancer Diagnostics Market Size by Region: 2018-2023
5.2.2 Global Prostate Cancer Diagnostics Market Size by Region (2024-2029)
6 Americas
6.1 Americas Prostate Cancer Diagnostics Market Size YoY Growth 2018-2029
6.2 Americas Prostate Cancer Diagnostics Market Size by Type
6.2.1 Americas Prostate Cancer Diagnostics Market Size by Type (2018-2023)
6.2.2 Americas Prostate Cancer Diagnostics Market Size by Type (2024-2029)
6.2.3 Americas Prostate Cancer Diagnostics Market Share by Type (2018-2029)
6.3 Americas Prostate Cancer Diagnostics Market Size by Application
6.3.1 Americas Prostate Cancer Diagnostics Market Size by Application (2018-2023)
6.3.2 Americas Prostate Cancer Diagnostics Market Size by Application (2024-2029)
6.3.3 Americas Prostate Cancer Diagnostics Market Share by Application (2018-2029)
6.4 Americas Prostate Cancer Diagnostics Market Facts & Figures by Country (2018, 2022 & 2029)
6.4.1 United States
6.4.2 Canada
6.4.3 Mexico
6.4.4 Brazil
7 EMEA
7.1 EMEA Prostate Cancer Diagnostics Market Size YoY Growth 2018-2029
7.2 EMEA Prostate Cancer Diagnostics Market Size by Type
7.2.1 EMEA Prostate Cancer Diagnostics Market Size by Type (2018-2023)
7.2.2 EMEA Prostate Cancer Diagnostics Market Size by Type (2024-2029)
7.2.3 EMEA Prostate Cancer Diagnostics Market Share by Type (2018-2029)
7.3 EMEA Prostate Cancer Diagnostics Market Size by Application
7.3.1 EMEA Prostate Cancer Diagnostics Market Size by Application (2018-2023)
7.3.2 EMEA Prostate Cancer Diagnostics Market Size by Application (2024-2029)
7.3.3 EMEA Prostate Cancer Diagnostics Market Share by Application (2018-2029)
7.4 EMEA Prostate Cancer Diagnostics Market Facts & Figures by Country (2018, 2022 & 2029)
7.4.1 Europe
7.4.2 Middle East
7.4.3 Africa
8 China
8.1 China Prostate Cancer Diagnostics Market Size YoY Growth 2018-2029
8.2 China Prostate Cancer Diagnostics Market Size by Type
8.2.1 China Prostate Cancer Diagnostics Market Size by Type (2018-2023)
8.2.2 China Prostate Cancer Diagnostics Market Size by Type (2024-2029)
8.2.3 China Prostate Cancer Diagnostics Market Share by Type (2018-2029)
8.3 China Prostate Cancer Diagnostics Market Size by Application
8.3.1 China Prostate Cancer Diagnostics Market Size by Application (2018-2023)
8.3.2 China Prostate Cancer Diagnostics Market Size by Application (2024-2029)
8.3.3 China Prostate Cancer Diagnostics Market Share by Application (2018-2029)
9 APAC (excluding China)
9.1 APAC Prostate Cancer Diagnostics Market Size YoY Growth 2018-2029
9.2 APAC Prostate Cancer Diagnostics Market Size by Type
9.2.1 APAC Prostate Cancer Diagnostics Market Size by Type (2018-2023)
9.2.2 APAC Prostate Cancer Diagnostics Market Size by Type (2024-2029)
9.2.3 APAC Prostate Cancer Diagnostics Market Share by Type (2018-2029)
9.3 APAC Prostate Cancer Diagnostics Market Size by Application
9.3.1 APAC Prostate Cancer Diagnostics Market Size by Application (2018-2023)
9.3.2 APAC Prostate Cancer Diagnostics Market Size by Application (2024-2029)
9.3.3 APAC Prostate Cancer Diagnostics Market Share by Application (2018-2029)
9.4 APAC Prostate Cancer Diagnostics Market Facts & Figures by Country (2018, 2022 & 2029)
9.4.1 Japan
9.4.2 South Korea
9.4.3 China Taiwan
9.4.4 Southeast Asia
9.4.5 India
10 Key Players Profiles
10.1 OPKO
10.1.1 OPKO Company Details
10.1.2 OPKO Business Overview
10.1.3 OPKO Prostate Cancer Diagnostics Introduction
10.1.4 OPKO Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.1.5 OPKO Recent Development
10.2 Genomic Health
10.2.1 Genomic Health Company Details
10.2.2 Genomic Health Business Overview
10.2.3 Genomic Health Prostate Cancer Diagnostics Introduction
10.2.4 Genomic Health Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.2.5 Genomic Health Recent Development
10.3 Abbott
10.3.1 Abbott Company Details
10.3.2 Abbott Business Overview
10.3.3 Abbott Prostate Cancer Diagnostics Introduction
10.3.4 Abbott Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.3.5 Abbott Recent Development
10.4 Beckman Coulter
10.4.1 Beckman Coulter Company Details
10.4.2 Beckman Coulter Business Overview
10.4.3 Beckman Coulter Prostate Cancer Diagnostics Introduction
10.4.4 Beckman Coulter Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.4.5 Beckman Coulter Recent Development
10.5 Siemens Healthcare
10.5.1 Siemens Healthcare Company Details
10.5.2 Siemens Healthcare Business Overview
10.5.3 Siemens Healthcare Prostate Cancer Diagnostics Introduction
10.5.4 Siemens Healthcare Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.5.5 Siemens Healthcare Recent Development
10.6 bioMeriux
10.6.1 bioMeriux Company Details
10.6.2 bioMeriux Business Overview
10.6.3 bioMeriux Prostate Cancer Diagnostics Introduction
10.6.4 bioMeriux Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.6.5 bioMeriux Recent Development
10.7 Roche
10.7.1 Roche Company Details
10.7.2 Roche Business Overview
10.7.3 Roche Prostate Cancer Diagnostics Introduction
10.7.4 Roche Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.7.5 Roche Recent Development
10.8 MDx Health
10.8.1 MDx Health Company Details
10.8.2 MDx Health Business Overview
10.8.3 MDx Health Prostate Cancer Diagnostics Introduction
10.8.4 MDx Health Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.8.5 MDx Health Recent Development
10.9 DiaSorin
10.9.1 DiaSorin Company Details
10.9.2 DiaSorin Business Overview
10.9.3 DiaSorin Prostate Cancer Diagnostics Introduction
10.9.4 DiaSorin Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.9.5 DiaSorin Recent Development
10.10 Myriad Genetics
10.10.1 Myriad Genetics Company Details
10.10.2 Myriad Genetics Business Overview
10.10.3 Myriad Genetics Prostate Cancer Diagnostics Introduction
10.10.4 Myriad Genetics Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.10.5 Myriad Genetics Recent Development
10.11 Ambry Genetics
10.11.1 Ambry Genetics Company Details
10.11.2 Ambry Genetics Business Overview
10.11.3 Ambry Genetics Prostate Cancer Diagnostics Introduction
10.11.4 Ambry Genetics Revenue in Prostate Cancer Diagnostics Business (2018-2023)
10.11.5 Ambry Genetics Recent Development
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details
OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics
*If Applicable.